Organization
Genitourinary Oncology Service
8 abstracts
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,
Abstract
A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma.Org: Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO).Org: Memorial Sloan Kettering Cancer Center, Adaptive Phage Therapeutics, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).Org: James P. Wilmot Cancer Center - Pluta, University of Rochester Medical Center, Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).Org: Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, Queen Mary University of London, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
Big data in oncology: Challenges and solutions.Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Genitourinary Oncology Service, Thoracic Oncology Service,
Abstract
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.Org: Dana-Farber Cancer Institute, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Janssen Research & Development,